How to Get Evenity (Romosozumab) in Arizona

What Is Romosozumab and Why Does It Matter for Arizona Patients?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation and decreases bone resorption, a dual mechanism unique among osteoporosis therapies. The FDA approved Evenity in April 2019 for postmenopausal women with osteoporosis at high risk for fracture (FDA label).

Arizona has roughly 1.2 million residents over age 65, and postmenopausal osteoporosis affects an estimated 25% of women in that age group according to National Osteoporosis Foundation prevalence data. The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone at 24 months (Saag et al., NEJM 2017). For Arizona patients with prior fragility fractures or T-scores at or below -2.5 who have not responded to first-line bisphosphonates, romosozumab represents a time-limited anabolic option before transitioning to maintenance antiresorptive therapy.

The prescribing pathway in Arizona involves several distinct steps: clinician evaluation, baseline laboratory work, insurance prior authorization, specialty pharmacy coordination, and monthly injection visits. Each step has state-specific details worth understanding before you begin.

Step 1: Find a Qualified Prescriber in Arizona

Arizona law permits MDs, DOs, nurse practitioners (NPs with full practice authority under A.R.S. § 32-1601), and physician assistants (PAs under supervising physician delegation) to prescribe Evenity. The most common prescribers are endocrinologists and rheumatologists, though some primary care physicians with osteoporosis expertise also initiate treatment.

Telehealth is a valid prescribing route. Arizona's telehealth parity law (A.R.S. § 20-1057.12) requires commercial insurers to cover telehealth visits at the same rate as in-person encounters. A provider licensed in Arizona can evaluate you via video, review your imaging and lab results, and write the Evenity prescription remotely. This is especially useful for patients in rural counties like Apache, Navajo, or Greenlee where bone-health specialists are scarce.

To locate a prescriber, start with the American Association of Clinical Endocrinology's "Find an Endocrinologist" directory or contact HealthRX for a telehealth consultation. Verify that the provider has experience with prior authorization for biologics, as Evenity's approval process is more complex than standard bisphosphonate prescriptions.

Step 2: Baseline Labs and Imaging

Before prescribing romosozumab, your clinician will order a set of baseline tests. These are not optional. The Endocrine Society's 2020 clinical practice guideline on postmenopausal osteoporosis recommends a standardized workup before initiating anabolic therapy (Eastell et al., J Clin Endocrinol Metab, 2019).

Required labs typically include:

• Serum calcium and albumin (to rule out hypocalcemia, a contraindication for Evenity)
• 25-hydroxyvitamin D (target ≥30 ng/mL; repleting low vitamin D before starting therapy is standard practice)
• Serum creatinine and eGFR (renal function assessment)
• Complete blood count (screening for secondary causes of bone loss)
• Serum phosphorus and alkaline phosphatase (baseline bone turnover markers)
• TSH (to exclude hyperthyroidism as a contributor)

A current DXA scan is also required. Most insurers require a DXA performed within the prior 24 months showing a T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip. The FRAX score may also be calculated. According to the National Osteoporosis Foundation guidelines, a 10-year hip fracture probability ≥3% or major osteoporotic fracture probability ≥20% supports treatment initiation (Camacho et al., Endocr Pract, 2020).

Arizona has DXA facilities in all major metro areas (Phoenix, Tucson, Mesa, Scottsdale, Chandler). Rural patients may need to travel to a regional imaging center, though some mobile DXA units serve underserved areas through partnerships with community health centers.

Step 3: Prior Authorization for Arizona Insurers

Nearly every commercial payer requires prior authorization for Evenity. The process varies by insurer but follows a general pattern. Your prescriber's office submits documentation including the DXA report, FRAX calculation, lab results, a list of prior osteoporosis treatments tried and failed (or contraindications to first-line agents), and a history of fragility fractures if applicable.

Common Arizona commercial insurers (Blue Cross Blue Shield of Arizona, UnitedHealthcare, Aetna, Cigna, and Banner/Aetna) generally require evidence of at least one of these before approving Evenity:

• Prior fragility fracture (vertebral, hip, or other nonvertebral site)
• Failure of or intolerance to an oral bisphosphonate (e.g., alendronate or risedronate)
• T-score of -3.0 or below even without fracture history
• Multiple risk factors placing the patient in a "very high fracture risk" category per the 2020 AACE/ACE guidelines

Turnaround time ranges from 5 to 14 business days. Some insurers offer expedited review in 72 hours for patients with acute vertebral fractures. If the initial request is denied, your prescriber can file a peer-to-peer review or formal appeal. According to Amgen's 2023 market access data, approximately 75% of Evenity prior authorization requests are approved on initial submission when documentation is complete.

Arizona AHCCCS (Medicaid) does not cover Evenity. Patients enrolled in AHCCCS will need to explore alternative coverage pathways. Amgen's Evenity copay card covers up to $12,000 per year for commercially insured patients, and the Amgen Safety Net Foundation provides free drug to qualifying uninsured or underinsured patients with household income at or below 300% of the federal poverty level (Amgen Assist).

Step 4: Specialty Pharmacy and Drug Delivery in Arizona

Evenity is distributed through specialty pharmacies, not standard retail pharmacies. Each dose consists of two prefilled syringes (105 mg each, administered sequentially to deliver the full 210 mg dose). The drug requires refrigeration between 2°C and 8°C and should not be frozen.

Major specialty pharmacies serving Arizona include Accredo (Express Scripts), CVS Specialty, OptumRx Specialty, and Biologics by McKesson. Your insurer's formulary dictates which specialty pharmacy you must use. Once approved, the pharmacy ships the drug either to your prescriber's office or directly to your home with cold-chain packaging.

Regarding 503A compounding pharmacies in Arizona: while the state does license 503A facilities, romosozumab is a humanized monoclonal antibody produced through recombinant DNA technology. It cannot be compounded by a 503A pharmacy. Biologics of this complexity require FDA-licensed manufacturing facilities. Any pharmacy claiming to compound romosozumab should be reported to the Arizona State Board of Pharmacy.

Step 5: Monthly Injection Protocol

Each injection visit takes approximately 15 to 30 minutes. The two subcutaneous injections are given in the abdomen, thigh, or upper arm. They must be administered at different injection sites. A healthcare professional performs the injections in a clinical setting; Evenity is not approved for self-administration.

Your options in Arizona include:

• Prescriber's office (endocrinology or rheumatology clinic)
• Infusion centers (many are located in Phoenix, Tucson, and Scottsdale; some accept walk-in injection appointments)
• Home health nursing (some insurers cover a visiting nurse for monthly injections, particularly for patients with mobility limitations)

The complete treatment course is 12 monthly doses. No more. The FDA label specifies that the bone-forming effect of romosozumab diminishes after 12 months because the anabolic window closes as sclerostin antibody exposure continues. After completing the 12-dose course, your provider should transition you to an antiresorptive agent (bisphosphonate or denosumab) to maintain the bone density gains. The ARCH trial showed that patients who transitioned from romosozumab to alendronate maintained fracture risk reduction through 24 months (Saag et al., NEJM 2017).

Cost and Financial Assistance in Arizona

The wholesale acquisition cost (WAC) for Evenity is approximately $1,825 per monthly dose, totaling roughly $21,900 for the full 12-month course. Actual out-of-pocket costs depend on insurance plan structure.

For commercially insured patients, Amgen's Evenity copay assistance program can reduce monthly copays to as little as $0 for eligible patients, up to $12,000 annually. This program does not apply to government-funded insurance (Medicare Part B, AHCCCS, Tricare).

Medicare Part B covers Evenity when administered in a physician's office or outpatient setting because it is a provider-administered injectable. Patients typically pay 20% coinsurance after meeting the Part B deductible ($240 in 2024). For a $1,825 dose, that means roughly $365 per month out of pocket. Medicare Supplement (Medigap) plans may cover part or all of that coinsurance.

For uninsured Arizona patients, the Amgen Safety Net Foundation may provide Evenity at no cost. Eligibility requires U.S. residency, no commercial or government insurance coverage for the drug, and household income ≤300% FPL. Application processing takes 2 to 4 weeks.

Cardiovascular Safety Considerations

Evenity carries an FDA boxed warning regarding potential increased risk of myocardial infarction, stroke, and cardiovascular death. This warning was added based on data from the ARCH trial, where the romosozumab group had a higher rate of adjudicated major adverse cardiac events (MACE) compared with the alendronate group during the first 12 months: 2.5% vs. 1.9% (Saag et al., NEJM 2017).

The FDA label states that Evenity should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Prescribers in Arizona should obtain a cardiovascular risk assessment before starting therapy. The FRAME trial (N=7,180), which compared romosozumab to placebo rather than an active comparator, did not show a statistically significant difference in cardiovascular events between groups (Cosman et al., NEJM 2016).

Dr. Felicia Cosman, professor of medicine at Columbia University, stated in a 2019 Endocrine Society commentary: "The cardiovascular signal in ARCH may reflect a protective effect of alendronate rather than a harmful effect of romosozumab, but until more data emerge, clinicians should screen for cardiovascular risk factors before prescribing" (Endocrine Society statement, 2019).

Your Arizona prescriber should assess blood pressure, lipid levels, diabetes status, smoking history, and any personal or family history of cardiovascular events before initiating Evenity.

Timeline: From First Appointment to First Injection

Understanding the full timeline helps with planning. Here is a realistic sequence for an Arizona patient:

• Week 1: Initial consultation (telehealth or in-person). Labs and DXA ordered.
• Weeks 1 to 2: Labs drawn at Quest, Sonora Quest, or LabCorp; DXA performed at an imaging facility.
• Week 2 to 3: Results reviewed. If Evenity is appropriate, prior authorization submitted.
• Weeks 3 to 5: Prior authorization processed (5 to 14 business days). Specialty pharmacy receives the prescription.
• Week 5 to 6: Specialty pharmacy ships the first dose. First injection administered.

Total time from initial appointment to first injection: approximately 4 to 6 weeks for a straightforward case. Delays in prior authorization, incomplete documentation, or the need for vitamin D repletion (which takes 8 to 12 weeks at high-dose ergocalciferol) can extend this timeline.

Monitoring During and After Treatment

During the 12-month course, your prescriber should check serum calcium within the first month and periodically thereafter, especially if you have renal impairment. Symptoms of hypocalcemia (tingling in fingers or lips, muscle cramps, spasms) warrant immediate lab evaluation.

A repeat DXA scan is typically ordered at month 12 to document bone mineral density response. The FRAME trial showed a mean lumbar spine BMD increase of 13.3% at 12 months with romosozumab compared with 0.0% with placebo (Cosman et al., NEJM 2016). Bone turnover markers (P1NP for formation, CTX for resorption) can also be tracked, though this is not universally done in clinical practice.

After completing 12 doses, the transition to antiresorptive therapy should happen without a gap. The 2020 AACE/ACE osteoporosis guideline explicitly warns against discontinuing anabolic therapy without follow-on antiresorptive treatment, as bone density gains can be lost rapidly (Camacho et al., Endocr Pract, 2020).